Inclusion Body Myositis (IBM) (Metabolic Disorder) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis – Drugs In Development, 2021, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 1 respectively.

Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (Musculoskeletal Disorders).

– The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AAVogen Inc

Abata Therapeutics

Abcuro Inc

Alzheon Inc

Cleave Therapeutics Inc

Kv1.3 Therapeutics

Leadiant Biosciences Inc

Milo Biotechnology LLC

Nobelpharma Co Ltd

PhaseBio Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Inclusion Body Myositis (IBM) - Overview

Inclusion Body Myositis (IBM) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Inclusion Body Myositis (IBM) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development

AAVogen Inc

Abata Therapeutics

Abcuro Inc

Alzheon Inc

Cleave Therapeutics Inc

Kv1.3 Therapeutics

Leadiant Biosciences Inc

Milo Biotechnology LLC

Nobelpharma Co Ltd

PhaseBio Pharmaceuticals Inc

Inclusion Body Myositis (IBM) - Drug Profiles

ABC-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aceneuramic acid ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALZ-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEXM-74 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene-Modified Cell Therapy for Inclusion Body Myositis (IBM) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Inclusion Body Myositis (IBM) - Dormant Projects

Inclusion Body Myositis (IBM) - Discontinued Products

Inclusion Body Myositis (IBM) - Product Development Milestones

Featured News & Press Releases

Jun 30, 2021: Abcuro and ImaginAb share initial results of study using novel technology for imaging T cell infiltration of skeletal muscle in patients with inclusion body myositis

Apr 01, 2021: Nobel Pharma announces notice of designation of orphan drug

Apr 25, 2018: New Data Supports Dalazatide from Kv

1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis

Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy

Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency

May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy

Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy

Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society

Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting

Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy

Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress

Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy

Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Inclusion Body Myositis (IBM), 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Inclusion Body Myositis (IBM) – Pipeline by AAVogen Inc, 2021

Inclusion Body Myositis (IBM) – Pipeline by Abata Therapeutics, 2021

Inclusion Body Myositis (IBM) – Pipeline by Abcuro Inc, 2021

Inclusion Body Myositis (IBM) – Pipeline by Alzheon Inc, 2021

Inclusion Body Myositis (IBM) – Pipeline by Cleave Therapeutics Inc, 2021

Inclusion Body Myositis (IBM) – Pipeline by Kv1.3 Therapeutics, 2021

Inclusion Body Myositis (IBM) – Pipeline by Leadiant Biosciences Inc, 2021

Inclusion Body Myositis (IBM) – Pipeline by Milo Biotechnology LLC, 2021

Inclusion Body Myositis (IBM) – Pipeline by Nobelpharma Co Ltd, 2021

Inclusion Body Myositis (IBM) – Pipeline by PhaseBio Pharmaceuticals Inc, 2021

Inclusion Body Myositis (IBM) – Dormant Projects, 2021

Inclusion Body Myositis (IBM) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Inclusion Body Myositis (IBM), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports